Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

CASI:

H.C. Wainwright is maintaining its Buy rating and $7 price target on CASI Pharamceuticals (CASI) today. Here is there reasoning for their price target

We maintain our Buy rating of CASI and our 12-month price target of $7.00 per share. We derive our price target based on the average of two valuation methods: (1) price-sales multiple analysis applying an 8x multiple to our 2025 sales estimate discounted at 12%; and (2) price-earnings multiple analysis applying an 18x multiple to our 2025 estimated earnings discounted at 12%. (1) clinical; (2) regulatory; (3) financial; and (4) intellectual property.”

Above quote was from Bret Jensen's Blog

Haven't done a recent calculation but from my last post on the subject

Right now CASI ownership by SPPI is capped at 13.42% and will go down w each CASI dilution. But that's OK, it's all bonus money.